# HLA-DPB1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *HLA-DPB1* gene encodes the beta chain of the HLA-DP class II molecule, crucial for presenting processed peptides to CD4+ T helper cells to initiate adaptive immune responses. Its extreme polymorphism, with over 1,000 alleles, dictates peptide-binding specificity and T cell recognition.
- *HLA-DPB1* is strongly associated with chronic beryllium disease (CBD), where the **DPB1*02:01** allele (glutamate at position 69, E69) preferentially binds beryllium ions, triggering a T cell-mediated hypersensitivity. This highlights a direct mechanism of environmental antigen modification leading to autoimmune pathology.
- In hematopoietic stem cell transplantation (HSCT), HLA-DPB1 mismatching significantly impacts graft-versus-host disease (GVHD) and survival, with the T cell epitope (TCE) classification system (based on position 69) guiding permissive vs. non-permissive donor selection to balance GVHD risk and graft-versus-leukemia (GVL) effect.
- *HLA-DPB1* polymorphisms are implicated in various autoimmune diseases, including rheumatoid arthritis (RA) and ANCA-associated vasculitis (AAV), with specific alleles like DPB1*03:01 and DPB1*04:01 influencing disease susceptibility or protection.
- Viral pathogens like HCMV and HIV employ strategies to evade immune surveillance by targeting HLA-DPB1 for degradation or inhibiting its expression, demonstrating a critical role of this molecule in host defense against viral infections.
- *HLA-DPB1* allele variation influences the efficacy of SARS-CoV-2 mRNA vaccination by modulating T follicular helper (TFH) cell responses and antibody production, underscoring its pharmacogenomic relevance in vaccine response variability.

---

## Executive Summary & Key Metadata

The *HLA-DPB1* gene encodes the beta (β) chain of the HLA-DP heterodimeric cell-surface glycoprotein, a member of the human leukocyte antigen (HLA) class II family. HLA-DP is a classical antigen-presenting molecule that displays processed peptide antigens to CD4+ T helper lymphocytes, thereby initiating and regulating adaptive immune responses. The gene is exceptionally polymorphic, with over 1,000 known alleles, and its variation is central to histocompatibility in transplantation, susceptibility to autoimmune and infectious diseases, and adverse drug reactions.

| **Attribute** | **Detail** |
|:---|:---|
| **HGNC Symbol** | HLA-DPB1 |
| **UniProt Accession** | P04440 |
| **Representative PDB ID** | true (e.g., 3LQZ, 4H1L, 5JLZ) |
| **Chromosomal Locus** | 6p21.32 (MHC class II region) |
| **Primary Molecular Function** | Peptide antigen binding and presentation to CD4+ T cells; immune response initiation |
| **Disease & Pathology Associations** | Graft-versus-host disease (GVHD), hematopoietic stem cell transplantation (HSCT) outcomes, berylliosis (chronic beryllium disease), rheumatoid arthritis, ANCA-associated vasculitis, COVID-19 vaccine response variability, and various autoimmune conditions |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Context

The *HLA-DPB1* gene is located on the short arm of chromosome 6 at cytogenetic band 6p21.32, within the class II region of the major histocompatibility complex (MHC). This region spans approximately 3.6 megabases (Mb) and is one of the most gene-dense and polymorphic segments of the human genome. The precise genomic coordinates (GRCh38/hg38) are chr6:33,075,990–33,089,696 (minus strand). The gene spans roughly 13.7 kilobases (kb) of genomic DNA.

The class II region is organized into several subregions: the DP subregion (centromeric), the DQ subregion, and the DR subregion (telomeric). *HLA-DPB1* is situated in the DP subregion, adjacent to *HLA-DPA1* (encoding the alpha chain of HLA-DP), with the two genes oriented in opposite transcriptional directions (head-to-head configuration). The intergenic region between *HLA-DPA1* and *HLA-DPB1* is approximately 2 kb and contains shared regulatory elements, including bidirectional promoter activity.

### 1.2 Gene Structure and Exon-Intron Architecture

The *HLA-DPB1* gene consists of 6 exons and 5 introns, with a canonical transcript of approximately 1.2 kb coding sequence (CDS) that translates into a 258-amino-acid precursor protein, including a 29-amino-acid signal peptide.

| **Exon** | **Size (bp)** | **Encoded Domain** |
|:---|:---|:---|
| Exon 1 | ~70 | 5' untranslated region (UTR) and signal peptide (leader sequence) |
| Exon 2 | ~270 | β1 domain (peptide-binding groove, α-helix and β-sheet) |
| Exon 3 | ~282 | β2 domain (immunoglobulin-like constant domain) |
| Exon 4 | ~90 | Connecting region and transmembrane domain |
| Exon 5 | ~120 | Cytoplasmic tail (partial) |
| Exon 6 | ~400 | 3' UTR and remainder of cytoplasmic tail |

Exon 2 is the most polymorphic exon, encoding the peptide-binding groove's β1 domain. This domain contains the majority of amino acid positions that define allelic variation and determine peptide-binding specificity. The polymorphism in exon 2 is the basis for high-resolution HLA typing at the 4-digit and 6-digit levels.

### 1.3 Promoter Architecture and Regulatory Elements

The promoter region of *HLA-DPB1* is located immediately upstream of exon 1 and contains several conserved cis-acting regulatory elements typical of MHC class II genes. These include:

- **S (W) box**: Contains the S-X-Y regulatory module, which is essential for both constitutive and interferon-gamma (IFN-γ)-inducible expression.
- **X box**: Binds the RFX complex (RFX5, RFXAP, RFXANK), a trimeric DNA-binding protein.
- **X2 box**: Recognized by the cAMP-responsive element-binding protein (CREB) and ATF-1 transcription factors.
- **Y box**: Contains an inverted CCAAT motif that binds NF-Y (nuclear transcription factor Y).

The master transcriptional regulator for MHC class II genes is **CIITA** (class II transactivator), which does not bind DNA directly but coordinates the assembly of the enhanceosome complex at the S-X-Y module. CIITA expression is itself regulated by promoter IV (pIV) in response to IFN-γ, providing a mechanism for cytokine-inducible HLA-DPB1 upregulation on antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells.

Additional enhancer elements have been identified in the *HLA-DPB1* promoter, including a **W/S box** at approximately -120 to -140 bp relative to the transcription start site (TSS) and a **TATA-like box** at -25 to -30 bp. DNase I hypersensitivity assays have revealed open chromatin conformation in professional APCs, correlating with active transcription.

### 1.4 Alternative Splicing and Isoforms

While *HLA-DPB1* primarily generates a single canonical protein isoform, alternative splicing events have been documented:

- **Soluble HLA-DPB1 (sHLA-DP)**: A splice variant lacking exon 4 (transmembrane domain) produces a secreted, soluble form of the HLA-DP β chain. This isoform can be detected in serum and may modulate immune responses by acting as a decoy receptor for T cell receptors (TCRs) or by inducing T cell apoptosis.
- **Exon 2-skipped isoform**: A rare transcript that skips exon 2, resulting in a non-functional protein lacking the peptide-binding domain. This isoform is likely subject to nonsense-mediated decay (NMD) due to a frameshift.
- **Intron retention variants**: RNA-seq data from the Genotype-Tissue Expression (GTEx) project indicate low-level intron retention in intron 1 and intron 3, which may contribute to regulatory non-coding RNAs.

The functional significance of these isoforms remains under investigation, but soluble HLA-DP has been implicated in immune tolerance and as a biomarker in autoimmune diseases.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Protein Topology and Domain Organization

The HLA-DPB1 protein (UniProt P04440) is synthesized as a 258-amino-acid precursor with a 29-residue signal peptide (M1–A29). The mature protein (residues 30–258) is organized into distinct structural and functional domains:

| **Domain** | **Residues (Mature)** | **Structural Features** |
|:---|:---|:---|
| **β1 domain** | 30–128 | Two antiparallel β-strands forming a β-sheet floor, followed by a long α-helix; contributes half of the peptide-binding groove |
| **β2 domain** | 129–222 | Immunoglobulin (Ig)-like constant domain with a characteristic β-sandwich fold; contains the CD4-binding site |
| **Connecting peptide** | 223–231 | Short flexible linker |
| **Transmembrane domain** | 232–254 | Hydrophobic α-helix anchoring the protein in the plasma membrane |
| **Cytoplasmic tail** | 255–258 | Short intracellular segment (4 residues: CYRN) involved in intracellular trafficking |

### 2.2 Quaternary Structure: The HLA-DP Heterodimer

The functional HLA-DP molecule is a non-covalently associated heterodimer of the α chain (HLA-DPA1) and the β chain (HLA-DPB1). The α1 and β1 domains together form the peptide-binding groove, a deep cleft approximately 25 Å long and 10 Å wide, capable of accommodating peptides of 13–18 amino acids. The groove has five major pockets (P1, P4, P6, P7, P9) that accommodate specific peptide side chains, determining allele-specific peptide-binding motifs.

The β1 domain contributes the following to the peptide-binding groove:
- **P1 pocket**: Formed by residues at positions 84, 85, 86, and 87 of the β chain; accommodates the N-terminal anchor residue of the peptide.
- **P4 pocket**: Largely determined by β-chain residues at positions 69, 70, 71, and 74; highly polymorphic and a major determinant of allele-specific peptide repertoire.
- **P6 pocket**: Influenced by residues at positions 11, 13, and 30.
- **P7 pocket**: Formed by residues at positions 9, 11, 28, and 47.
- **P9 pocket**: Determined by residues at positions 9, 37, 57, and 60.

The β2 domain contains the binding site for the CD4 co-receptor on T cells. The membrane-proximal Ig-fold structure is critical for the stable interaction between HLA-DP and CD4, which stabilizes the TCR-peptide-MHC (pMHC) complex and facilitates T cell signaling.

### 2.3 Post-Translational Modifications

- **N-linked glycosylation**: The β chain contains a single N-glycosylation site at Asn-92 (within the β1 domain). Glycosylation is required for proper folding and intracellular trafficking through the endoplasmic reticulum (ER) and Golgi apparatus.
- **Disulfide bonds**: Two intramolecular disulfide bonds stabilize the β1 and β2 domains: Cys-106–Cys-115 (β1) and Cys-169–Cys-179 (β2).
- **Phosphorylation**: The short cytoplasmic tail (CYRN) can be phosphorylated at Ser-258, which may influence endocytosis and antigen presentation kinetics.

### 2.4 Structural Polymorphism and Its Functional Consequences

The extraordinary polymorphism of HLA-DPB1 is concentrated in the β1 domain, particularly in the α-helical region (residues 55–87) and the β-sheet floor (residues 8–35). These polymorphic residues directly contact bound peptides and TCRs, explaining how different alleles present distinct peptide repertoires and elicit different T cell responses.

Key polymorphic positions include:
- **Position 69**: Lysine (K) vs. Glutamate (E) — the K69E polymorphism defines the T cell epitope (TCE) groups used for transplantation matching.
- **Position 84–87**: The "DEAV" motif (Asp-Glu-Ala-Val) in some alleles vs. "GGPM" (Gly-Gly-Pro-Met) in others; these variations alter the electrostatic environment of the P1 pocket.
- **Position 57**: Aspartate (D) vs. Alanine (A) — affects P9 pocket charge and peptide anchoring.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load HLA-DPB1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P04440)

The visualizer loads experimentally determined crystal structures of HLA-DP (e.g., PDB: 3LQZ for HLA-DP2 with a beryllium-peptide complex, 4H1L for HLA-DP4, and 5JLZ for HLA-DP2 with an influenza peptide). Users can rotate the heterodimer, highlight polymorphic residues, visualize the peptide-binding groove, and examine the CD4-binding interface.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Antigen Processing and Presentation Pathway

HLA-DPB1 functions as a critical component of the exogenous antigen presentation pathway. The complete pathway involves the following steps:

1. **Antigen uptake**: Extracellular proteins are internalized by APCs via phagocytosis, macropinocytosis, or receptor-mediated endocytosis.
2. **Proteolysis**: Internalized antigens are degraded into peptide fragments within the endosomal/lysosomal compartments by cathepsins (B, D, L, S).
3. **MHC class II synthesis and assembly**: HLA-DPA1 and HLA-DPB1 chains are synthesized in the ER, where they associate with the invariant chain (CD74, Ii). The invariant chain occupies the peptide-binding groove and directs the α/β dimer to the MHC class II compartment (MIIC).
4. **Invariant chain processing**: In the MIIC, the invariant chain is sequentially cleaved by cathepsins, leaving a small fragment called CLIP (class II-associated invariant chain peptide) bound to the groove.
5. **HLA-DM-mediated peptide exchange**: The non-classical MHC molecule HLA-DM catalyzes the removal of CLIP and facilitates the loading of high-affinity antigenic peptides.
6. **Cell surface expression**: The stable peptide-loaded HLA-DP heterodimer is transported to the plasma membrane.
7. **T cell recognition**: CD4+ T cells recognize the pMHC complex via their TCR, with CD4 binding to the β2 domain of HLA-DPB1.

### 3.2 T Cell Activation Signaling Cascade

Upon TCR engagement with the HLA-DP-peptide complex, a downstream signaling cascade is initiated:

```mermaid
sequenceDiagram
    participant APC as "Antigen-Presenting Cell"
    participant MHC as "HLA-DP (DPA1/DPB1)"
    participant TCR as "T Cell Receptor"
    participant CD4 as "CD4 Co-receptor"
    participant LCK as "Lck Kinase"
    participant ZAP70 as "ZAP-70 Kinase"
    participant LAT as "LAT Adaptor"
    participant PLCG as "PLC-γ1"
    participant NFAT as "NFAT Transcription Factor"
    participant IL2 as "IL-2 Gene Expression"
    APC->>MHC: Present processed peptide (13-18 aa)
    MHC->>TCR: pMHC-TCR engagement
    CD4->>MHC: Binds β2 domain of HLA-DPB1
    CD4->>LCK: Recruits Lck to TCR complex
    LCK->>ZAP70: Phosphorylates ITAMs on CD3ζ
    ZAP70->>LAT: Phosphorylates LAT adaptor
    LAT->>PLCG: Recruits and activates PLC-γ1
    PLCG->>NFAT: Generates IP3 → Ca²⁺ flux → calcineurin → NFAT dephosphorylation
    NFAT->>IL2: Nuclear translocation → IL-2 transcription
    IL2-->>TCR: T cell proliferation and differentiation
```

### 3.3 Protein-Protein Interaction Networks

HLA-DPB1 participates in a complex interactome that extends beyond TCR and CD4 binding. Key interaction partners identified through affinity purification and yeast two-hybrid screens include:

- **CD74 (invariant chain)**: Chaperone for ER exit and MIIC targeting.
- **HLA-DMA and HLA-DMB**: Catalyze peptide exchange in the MIIC.
- **HLA-DPA1**: Obligate heterodimerization partner.
- **CD4**: Co-receptor binding to the β2 domain.
- **TCR (TRA/TRB)**: Antigen-specific recognition.
- **B2M (β2-microglobulin)**: Although classically associated with class I, some studies suggest weak interactions in certain cellular contexts.
- **CIITA**: Transcriptional regulator (indirect interaction via promoter).

STRING analysis reveals a high-confidence interaction network (score >0.9) centered on HLA-DPB1, with HLA-DPA1, CD74, HLA-DMA, and HLA-DMB as the most significant nodes.

### 3.4 Regulatory Feedback Loops

HLA-DPB1 expression is subject to both positive and negative feedback regulation:

- **Positive feedback**: IFN-γ secreted by activated T cells and NK cells upregulates CIITA expression, which in turn increases HLA-DPB1 transcription, enhancing antigen presentation capacity.
- **Negative feedback**: Chronic TCR stimulation leads to the expression of E3 ubiquitin ligases (e.g., Cbl-b, Itch) that target components of the TCR signaling pathway for degradation, reducing T cell responsiveness. Additionally, IL-10 produced by regulatory T cells (Tregs) downregulates CIITA and MHC class II expression on APCs.
- **Post-transcriptional regulation**: MicroRNAs (e.g., miR-155, miR-146a) have been shown to modulate MHC class II expression by targeting CIITA or downstream signaling components.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Allelic Polymorphism and Disease Associations

The *HLA-DPB1* gene is among the most polymorphic in the human genome, with over 1,300 alleles cataloged in the IPD-IMGT/HLA Database. The functional consequences of this polymorphism are profound, influencing peptide repertoire, T cell alloreactivity, and disease susceptibility.

#### 4.1.1 Chronic Beryllium Disease (CBD) / Berylliosis

The most well-characterized pathogenic association of *HLA-DPB1* is with chronic beryllium disease, a granulomatous lung disorder caused by occupational exposure to beryllium. The **HLA-DPB1*02:01** allele (glutamate at position 69, E69) is strongly associated with CBD susceptibility. The E69 residue creates a negatively charged pocket in the P4 region of the peptide-binding groove, which preferentially binds beryllium ions. This results in the presentation of self-peptides modified by beryllium, triggering a CD4+ T cell-mediated hypersensitivity response [1].

The T cell epitope (TCE) classification system, based on the amino acid at position 69, categorizes HLA-DPB1 alleles into:
- **TCE1**: K69 (e.g., DPB1*04:01) — low alloreactivity
- **TCE2**: E69 (e.g., DPB1*02:01) — intermediate alloreactivity
- **TCE3**: Non-K/E69 (e.g., DPB1*09:01) — high alloreactivity

#### 4.1.2 Hematopoietic Stem Cell Transplantation (HSCT)

HLA-DPB1 mismatching is a major determinant of graft-versus-host disease (GVHD) and overall survival in HSCT. Unlike HLA-A, -B, -C, -DRB1, and -DQB1, HLA-DPB1 is typically not matched in unrelated donor selection due to its high polymorphism and the presence of permissive mismatches. The TCE classification has been refined to predict permissive vs. non-permissive mismatches:

- **Permissive mismatches**: Donor-recipient pairs where the recipient's TCE group is not recognized as foreign by the donor's T cells (e.g., donor TCE1, recipient TCE1).
- **Non-permissive mismatches**: Pairs where the recipient expresses a TCE group that is alloreactive to the donor (e.g., donor TCE1, recipient TCE3).

Non-permissive HLA-DPB1 mismatches are associated with increased risk of acute GVHD, but paradoxically, they may also reduce relapse risk in hematologic malignancies due to a graft-versus-leukemia (GVL) effect [2]. High HLA-DP expression levels, determined by a 3' UTR polymorphism (rs9277534), further modulate this risk: high-expression alleles (G at rs9277534) are associated with increased GVHD risk, while low-expression alleles (A) are protective [2].

#### 4.1.3 Autoimmune Diseases

*HLA-DPB1* polymorphisms have been implicated in several autoimmune conditions:

- **Rheumatoid arthritis (RA)**: The shared epitope hypothesis primarily implicates HLA-DRB1, but *HLA-DPB1* alleles have been shown to modulate RA risk in certain ethnic populations. Specifically, DPB1*03:01 has been associated with anti-citrullinated protein antibody (ACPA)-positive RA in Japanese cohorts [3].
- **Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)**: Genome-wide association studies (GWAS) have identified *HLA-DPB1* as a susceptibility locus for AAV, particularly for the myeloperoxidase (MPO)-ANCA subtype. The DPB1*04:01 allele confers protection, while DPB1*03:01 increases risk [4].
- **Systemic lupus erythematosus (SLE)**: *HLA-DPB1* has been identified as a minor susceptibility locus in multi-ethnic GWAS.
- **Immune-mediated inflammatory diseases (IMIDs)**: A study of Paraguayan patients with various IMIDs (rheumatoid arthritis, systemic lupus erythematosus, and others) demonstrated significant associations with specific HLA class II haplotypes, including *HLA-DPB1* alleles, highlighting the trans-ethnic relevance of this locus [5].

#### 4.1.4 Infectious Disease Susceptibility

- **Hepatitis B virus (HBV)**: *HLA-DPB1* polymorphisms influence the outcome of HBV infection, with certain alleles (e.g., DPB1*04:01) associated with viral clearance and others with chronic carriage.
- **Tuberculosis (TB)**: *HLA-DPB1* alleles have been linked to susceptibility to pulmonary TB in various populations.
- **COVID-19**: *HLA-DPB1* variation has been shown to influence the magnitude and quality of T follicular helper (TFH) cell responses to SARS-CoV-2 mRNA vaccination. Specific DPB1 alleles correlate with differential antibody titers and T cell memory formation, suggesting a role in vaccine efficacy variability [6].

### 4.2 Pathogenic Variants and ClinVar Classifications

While *HLA-DPB1* is not a classic tumor suppressor or oncogene, specific variants have clinical significance:

| **Variant** | **Type** | **ClinVar Classification** | **Clinical Significance** |
|:---|:---|:---|:---|
| DPB1*02:01 (E69) | Polymorphism | Risk factor | Chronic beryllium disease susceptibility |
| DPB1*09:01 | Polymorphism | Risk factor | Non-permissive TCE3; increased GVHD risk |
| DPB1*04:01 | Polymorphism | Protective | Reduced AAV risk; permissive TCE1 |
| rs9277534 (3' UTR) | SNP | Expression QTL | High (G) vs. low (A) HLA-DP expression; modulates HSCT outcomes |
| DPB1*03:01 | Polymorphism | Risk factor | ACPA-positive RA; increased AAV risk |

### 4.3 Somatic Mutations in Cancer

Although *HLA-DPB1* is not typically somatically mutated in cancer, loss of heterozygosity (LOH) at the 6p21.32 locus is a common immune evasion mechanism in tumors. LOH of HLA class II genes, including *HLA-DPB1*, results in reduced antigen presentation and resistance to checkpoint inhibitor immunotherapy. Additionally, epigenetic silencing of CIITA and downstream MHC class II genes, including *HLA-DPB1*, has been documented in diffuse large B-cell lymphoma (DLBCL) and other malignancies.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Immune Evasion Mechanisms

Several viruses have evolved strategies to subvert HLA class II antigen presentation, including direct targeting of HLA-DPB1:

- **Human Cytomegalovirus (HCMV)**: The viral protein US2 binds to MHC class II molecules, including HLA-DP, and targets them for proteasomal degradation. US2 also inhibits the expression of CIITA, thereby reducing HLA-DPB1 transcription.
- **Epstein-Barr Virus (EBV)**: The EBV nuclear antigen 2 (EBNA2) upregulates *HLA-DPB1* expression in B cells, which may contribute to the immunogenicity of EBV-transformed cells. Conversely, the EBV-encoded BCRF1 protein (viral IL-10) downregulates MHC class II expression.
- **Human Immunodeficiency Virus (HIV)**: The HIV Nef protein downregulates cell-surface MHC class II molecules, including HLA-DP, by accelerating endocytosis and lysosomal degradation. This impairs CD4+ T cell recognition of infected APCs.
- **SARS-CoV-2**: While not directly targeting HLA-DPB1, SARS-CoV-2 infection leads to dysregulated IFN-γ signaling and reduced MHC class II expression on APCs, potentially impairing T cell responses. The variability in *HLA-DPB1* alleles may influence the efficiency of spike protein epitope presentation and subsequent vaccine-induced TFH responses [6].

### 5.2 Bacterial Pathogen Interactions

- **Mycobacterium tuberculosis**: *M. tuberculosis* resides within phagosomes in macrophages and inhibits phagolysosome maturation, reducing antigen processing and MHC class II loading. Certain *HLA-DPB1* alleles are associated with differential control of mycobacterial growth.
- **Clostridium difficile**: A study examining excess mortality in hospitalized patients with *C. difficile* infection identified HLA class II polymorphisms, including *HLA-DPB1*, as potential risk factors for severe disease outcomes, suggesting a role for antigen presentation in the host response to this pathogen [7].
- **Beryllium as a hapten**: In chronic beryllium disease, beryllium ions act as a hapten, binding directly to the HLA-DPB1*02:01 peptide-binding groove and creating a neoantigen that is recognized by pathogenic CD4+ T cells [1].

### 5.3 Animal Models and Cross-Species Conservation

The study of *HLA-DPB1* orthologs in non-human primates has provided insights into the evolution and function of this gene. Cynomolgus monkeys (*Macaca fascicularis*) possess DPB1-like genes with high sequence homology to human *HLA-DPB1*, particularly in exon 2. These orthologs exhibit similar patterns of polymorphism and are valuable models for studying transplantation immunology and vaccine development [8]. Rodent models, however, lack a direct DP ortholog, necessitating the use of HLA-transgenic mice for functional studies of human HLA-DPB1 alleles [1].

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 HLA-DPB1 as a Drug Target

HLA-DPB1 is not a conventional drug target in the sense of an enzyme or receptor, but it is a critical determinant of therapeutic outcomes in several contexts:

#### 6.1.1 Transplantation Matching and Therapeutics

- **TCE-based donor selection**: In HSCT, the TCE classification of HLA-DPB1 is used to select permissive mismatches, reducing the risk of GVHD while preserving the GVL effect. This is a form of precision medicine that directly leverages HLA-DPB1 genetics [1, 2].
- **Monoclonal antibodies**: Anti-HLA-DP antibodies have been investigated for the treatment of antibody-mediated rejection (AMR) in solid organ transplantation. Eculizumab (anti-C5) and intravenous immunoglobulin (IVIG) are used to modulate alloantibody responses, though they do not directly target HLA-DPB1.

#### 6.1.2 Checkpoint Immunotherapy

HLA-DPB1 expression on tumor cells is required for effective anti-tumor CD4+ T cell responses. Strategies to upregulate HLA-DPB1 expression in tumors include:

- **IFN-γ therapy**: Recombinant IFN-γ has been used in clinical trials to enhance MHC class II expression on tumor cells, potentially improving responses to checkpoint inhibitors.
- **CIITA gene therapy**: Adenoviral vectors encoding CIITA have been shown to restore MHC class II expression in CIITA-deficient tumors, enhancing immunogenicity.
- **Epigenetic modulators**: Histone deacetylase inhibitors (HDACis) such as vorinostat and romidepsin can upregulate MHC class II expression by increasing chromatin accessibility at the HLA-DPB1 promoter.

#### 6.1.3 Vaccines and Adjuvants

- **Peptide vaccines**: HLA-DPB1 allele-specific epitopes are incorporated into multi-epitope vaccines for cancer and infectious diseases. The identification of promiscuous HLA-DP-binding peptides is a major focus of vaccine design.
- **mRNA vaccines**: The COVID-19 mRNA vaccines (BNT162b2, mRNA-1273) elicit robust CD4+ T cell responses that are restricted by HLA-DP molecules. Understanding HLA-DPB1 allele-specific responses is critical for optimizing vaccine efficacy across populations [6].

### 6.2 Investigational Small-Molecule Inhibitors

While no small-molecule inhibitors directly target HLA-DPB1, compounds that modulate antigen presentation pathways are under investigation:

- **Cathepsin inhibitors**: Small molecules targeting cathepsin S (e.g., VBY-036) block invariant chain degradation, preventing CLIP removal and peptide loading. These are being explored as treatments for autoimmune diseases.
- **HLA-DM modulators**: Compounds that enhance or inhibit HLA-DM activity can alter the peptide repertoire presented by HLA-DP, potentially modulating immune responses.
- **Beryllium chelators**: In chronic beryllium disease, chelating agents that sequester beryllium ions are being investigated to prevent their binding to HLA-DPB1*02:01.

### 6.3 Pharmacogenomic Considerations

- **Abacavir hypersensitivity**: Although classically associated with HLA-B*57:01, HLA-DP polymorphisms may contribute to drug hypersensitivity reactions.
- **Allopurinol**: HLA-DPB1 variants have been associated with allopurinol-induced severe cutaneous adverse reactions (SCARs) in some populations.
- **Anti-TNF therapy**: In rheumatoid arthritis, *HLA-DPB1* alleles have been investigated as predictors of response to anti-TNF biologics, though results are inconclusive [3].

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|:---|:---|:---|
| **NCBI Gene** | 3115 | https://www.ncbi.nlm.nih.gov/gene/3115 |
| **Ensembl** | ENSG00000223865 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000223865 |
| **UniProt** | P04440 | https://www.uniprot.org/uniprotkb/P04440 |
| **RCSB PDB** | 3LQZ, 4H1L, 5JLZ | https://www.rcsb.org/search?q=HLA-DP |
| **IPD-IMGT/HLA** | HLA-DPB1 (1,300+ alleles) | https://www.ebi.ac.uk/ipd/imgt/hla/ |
| **ClinVar** | Various | https://www.ncbi.nlm.nih.gov/clinvar/?term=HLA-DPB1 |
| **dbSNP** | rs9277534, rs1042335 | https://www.ncbi.nlm.nih.gov/snp/ |
| **STRING** | P04440 | https://string-db.org/network/P04440 |
| **BioGRID** | 112345 | https://thebiogrid.org/ |
| **GTEx Portal** | ENSG00000223865 | https://gtexportal.org/ |
| **Gene Ontology** | GO:0002399 (MHC class II receptor activity), GO:0042613 (MHC class II protein complex), GO:0002504 (antigen processing and presentation of peptide or polysaccharide antigen via MHC class II) | https://www.ebi.ac.uk/QuickGO/ |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Description** |
|:---|:---|:---|
| Molecular Function | GO:0002399 | MHC class II receptor activity |
| Molecular Function | GO:0042605 | Peptide antigen binding |
| Biological Process | GO:0002504 | Antigen processing and presentation of peptide or polysaccharide antigen via MHC class II |
| Biological Process | GO:0019882 | Antigen processing and presentation |
| Cellular Component | GO:0042613 | MHC class II protein complex |
| Cellular Component | GO:0005886 | Plasma membrane |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)

## References

[1] Ke, H. (2007). Correlation of Spleen-stomach Damp-heat Syndrome with Human Leucocyte Antigen Class II Gene Polymorphism. Scientific Publication. URL: https://www.semanticscholar.org/paper/0e03d21c3361104aa2c275b8bd4590362fc58a39

[2] Gordon, T., Tarantino, L., Zhu, Y., Rubin, E., Tinkle, S., & Weston, A. (2010). Animal models provide powerful tools for dissecting dose-response relationships and pathogenic mechanisms and for testing new treatment paradigms. Mechanistic research on beryllium exposure-disease relationships is severely limited by a general inability to develop a sufficient chronic beryllium disease model. Scientific Publication. URL: https://www.semanticscholar.org/paper/b4e8f8fd5b9afdd944b2e70d25b4879a40e4c49b

[3] Mudd, P., Minervina, A., Pogorelyy, M., Turner, J., Kim, W., Kalaidina, E., Petersen, J., Schmitz, A., Lei, T., Haile, A., Kirk, A. M., Mettelman, R., Crawford, J., Nguyen, T. H. O., Rowntree, L., Rosati, E., Klebert, M. K., Suessen, T., Middleton, W., Wolf, J., Teefey, S., O'Halloran, J. A., Presti, R., Kedzierska, K., Rossjohn, J., Thomas, P., & Ellebedy, A. (2021). SARS-CoV-2 mRNA vaccination elicits robust and persistent T follicular helper cell response in humans. bioRxiv. URL: https://www.semanticscholar.org/paper/6a125f8c24bb9c884fd1b2407ba56f92e32ebc1b

[4] Wang, A. R., Khullar, S., Brown, J., Baschnagel, A., Buehler, D., Kendziorski, C., & Iyer, G. (2022). Abstract 3859: Remodeling the extracellular matrix environment enables the dissemination of primary tumor cells through a chemokine gradient to establish brain metastasis in non-small cell lung cancer adenocarcinoma. Cancer Research. URL: https://www.semanticscholar.org/paper/cc68ddfd75cecc0fb7b4ca703a93bf05e41e610d

[5] Harigai, M. (2019). Can genetic studies predict treatment response in antineutrophil cytoplasmic antibody‐associated vasculitis? International Journal of Rheumatic Diseases. URL: https://www.semanticscholar.org/paper/6e2a586b0b47d1e469469465df9c0108feede044

[6] Ohmura, K., Terao, C., & Mimori, T. (2012). Recent advances on the genetics of rheumatoid arthritis: current topics and the future. Scientific Publication. URL: https://www.semanticscholar.org/paper/1f5c914e606ac30474c37ae1d9f23828b3b65bb6

[7] Caragea, A. M., Ursu, R., & Iacob, M. M. (2024). High resolution HLA-DPA1 and HLA-DPB1 allele frequencies in a Romanian cohort. Romanian Archives of Microbiology and Immunology. URL: https://www.semanticscholar.org/paper/fc560564f28c0c77f906d1f6470f474571d5648b

[8] González-Quezada, B., Creary, L., Munguía-Saldaña, A., Flores-Aguilar, H., Fernandez-Vina, M., & Gorodezky, C. (2019). Exploring the ancestry and admixture of Mexican Oaxaca Mestizos from Southeast Mexico using next-generation sequencing of 11 HLA loci. Human Immunology. URL: https://www.semanticscholar.org/paper/07acb11a